Intensive therapy before or during the conditioning regimen of allogeneic marrow transplantation in adult acute lymphoblastic leukemia patients: we must choose to reduce Toxicity--a Groupe Ouest-Est d'Etude des Leucemies et Autres Maladies du Sang study.
暂无分享,去创建一个
M. Bernard | E. Deconinck | N. Ifrah | N. Milpied | J. Jouet | C. Berthou | M. Hunault | B. Lioure | M. Delain | J. Boiron | B. Desablens | D. Guyotat | F. Witz | B. Pignon | M. Renaud | P. Casassus
[1] M. Béné,et al. Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial. , 2004, Blood.
[2] J. Bourhis,et al. A potential graft-versus-leukemia effect after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: results from the French Bone Marrow Transplantation Society , 2003, Bone Marrow Transplantation.
[3] O. Ottmann,et al. Targeted therapies in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. , 2002, Seminars in hematology.
[4] D. Hoelzer,et al. Recent approaches in acute lymphoblastic leukemia in adults. , 2002, Critical reviews in oncology/hematology.
[5] L. Damon,et al. Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] S. Piantadosi,et al. Long-term follow-up of intensive ara-C-based chemotherapy followed by bone marrow transplantation for adult acute lymphoblastic leukemia: impact of induction Ara-C dose and post-remission therapy. , 2002, Leukemia research.
[7] M. Baccarani,et al. Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. , 2002, Blood.
[8] M. Bernard,et al. Daunorubicin continuous infusion induces more toxicity than bolus infusion in acute lymphoblastic leukemia induction regimen: a randomized study , 2001, Leukemia.
[9] B. Löwenberg,et al. Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: strong graft-versus-leukemia effect and risk factors determining outcome. , 2001, Blood.
[10] G. Todeschini. High-dose anthracycline induction in adult acute lymphocytic leukemia. , 2001, Hematology/oncology clinics of North America.
[11] D. Hoelzer,et al. Recent approaches in acute lymphoblastic leukemia in adults. , 2000, Reviews in clinical and experimental hematology.
[12] D. Hoelzer,et al. New approaches to acute lymphoblastic leukemia in adults: where do we go? , 2000, Seminars in oncology.
[13] N. Ifrah,et al. Intensive short term therapy with granulocyte‐macrophage–colony stimulating factor support, similar to therapy for acute myeloblastic leukemia, does not improve overall results for adults with acute lymphoblastic leukemia , 1999 .
[14] M. Tanimoto,et al. Chemotherapy vs HLA-identical sibling bone marrow transplants for adults with acute lymphoblastic leukemia in first remission , 1998, Bone Marrow Transplantation.
[15] E. Deconinck,et al. Allogeneic bone marrow transplantation for high-risk acute lymphoblastic leukemia in first remission: long-term results for 42 patients conditioned with an intensified regimen (TBI, high-dose Ara-C and melphalan) , 1997, Bone Marrow Transplantation.
[16] A Orfao,et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). , 1995, Leukemia.
[17] D. Blaise,et al. Consolidation treatment of adult acute lymphoblastic leukemia: a prospective, randomized trial comparing allogeneic versus autologous bone marrow transplantation and testing the impact of recombinant interleukin-2 after autologous bone marrow transplantation. BGMT Group. , 1995, Blood.
[18] C. Sebban,et al. Allogeneic bone marrow transplantation in adult acute lymphoblastic leukemia in first complete remission: a comparative study. French Group of Therapy of Adult Acute Lymphoblastic Leukemia. , 1994, Journal of Clinical Oncology.
[19] R. Bouabdallah,et al. Bone marrow transplantation in 63 adult patients with acute lymphoblastic leukemia in first complete remission. , 1994, Bone marrow transplantation.
[20] E. Thiel,et al. Chemotherapy compared with bone marrow transplantation for adults with acute lymphoblastic leukemia in first remission. , 1991, Annals of internal medicine.
[21] K. Sullivan,et al. Busulfan, cyclophosphamide and fractionated total body irradiation as a preparatory regimen for marrow transplantation in patients with advanced hematological malignancies: a phase I study. , 1989, Bone marrow transplantation.
[22] N. Nissen,et al. Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. , 1982, Blood.
[23] H. Gralnick,et al. Proposals for the Classification of the Acute Leukaemias French‐American‐British (FAB) Co‐operative Group , 1976, British journal of haematology.
[24] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[25] F. Appelbaum,et al. Comparison of the L10M consolidation regimen to an alternative regimen including escalating methotrexate/L-asparaginase for adult acute lymphoblastic leukemia: a Southwest Oncology Group Study , 2001, Leukemia.
[26] T. Barbui,et al. Risk-oriented postremission strategies in adult acute lymphoblastic leukemia: prospective confirmation of anthracycline activity in standard-risk class and role of hematopoietic stem cell transplants in high-risk groups. , 2001, The hematology journal : the official journal of the European Haematology Association.
[27] Taylor Murray,et al. Cancer statistics, 2000 , 2000, CA: a cancer journal for clinicians.
[28] Barrett Aj. Allogeneic bone marrow transplantation for acute lymphoblastic leukaemia , 1992 .
[29] J. Rossi,et al. Allogeneic or autologous bone marrow transplantation for acute lymphoblastic leukemia in first complete remission. , 1990, Bone marrow transplantation.
[30] D. Harnden,et al. An international system for human cytogenetic nomenclature (1985) : ISCN (1985) : report of the Standing Committee on Human Cytogenetic Nomenclature , 1985 .